CILTACABTAGENE AUTOLEUCEL
UNII 0L1F17908Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Ciltacabtagene Autoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 0L1F17908Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) 2594775. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

0L1F17908Q

CAS Registry Number

N/A

RxNorm Concept ID

2594775

Detailed Substance Profile

Preferred Name

CILTACABTAGENE AUTOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

0L1F17908Q

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C148498

National Cancer Institute reference terminology for clinical and research data.

INN ID

11131

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-76

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ciltacabtagene Autoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CILTACABTAGENE AUTOLEUCEL

Common Names & Synonyms

AUTOLOGOUS BI-EPITOPE BCMA-TARGETED CAR T-CELLS JNJ-68284528

AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)-DERIVED T LYMPHOCYTES TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODINGA CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING TWO EPITOPES OF THE HUMAN B CELL MATURATION ANTIGEN (BCMA) UNDER THE CONTROL OF A HUMAN ELONGATION FACTOR 1 ALPHA (EF1.ALPHA.) PROMOTER THE CODING SEQUENCE COMPRISES A HUMAN CD8 ALPHA SIGNAL PEPTIDE (CD8.ALPHA. SP), A BCMA TARGETING DOMAIN CONSISTING OF TWO VARIABLE HEAVY CHAIN-ONLY ANTIBODIES (VHH1 AND VHH2) TARGETING TWO DISTINCT BCMA EPITOPES, A HUMAN CD8 ALPHA HINGE AND TRANSMEMBRANE DOMAIN (CD8.ALPHA. HINGE + TM), A HUMAN CD137 CYTOPLASMIC DOMAIN (4-1BB) AND A HUMAN CD3 ZETA CYTOPLASMIC DOMAIN (CD3.ZETA.). THE VECTOR GENOME CONTAINS A CHIMERIC ROUS SARCOMA VIRUS (RSV)/TRUNCATED 5'LTR AND A SELF-INACTIVATING 3'LTR-SIN (.DELTA.-U3)

CILTACABTAGENE AUTOLEUCEL [INN]

CILTACABTAGENE AUTOLEUCEL [USAN]

CILTACABTAGENE AUTOLEUCEL [WHO-DD]

LCAR-B38M-TRANSDUCED CAR-T CELLS JNJ-68284528